Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q4 2018 Earnings Presentation
12 slides from Q-linea Ab's earnings presentation, February 2019
Slide 1: Presentation Q4(18)
Presentation Q4(18) Jonas Jarvius, CEO Anders Lundin, CFO STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea in brief
Headquarters in Uppsala Q-linea in brief Introduction to the company • Q-linea is developing disruptive solutions for faster Lead product ASTar™ infectious disease diagnostics, first product for sepsis Introduction to the company • 78 employees & consultants at year end • Successful private placemen
Slide 4: What is Sepsis
What is Sepsis Sepsis Septic chock Sepsis is all about TIME • Deadly organ • Sepsis progressed T TEMPERATURE dysfunction caused and need higher than normal by a dysregulated treatment to systemic immune sustain blood INFECTION response caused by pressure and I May have signs and an infection. lactat
Slide 5: Combating our time's most urgent healthcare problem - Sepsis
Combating our time’s most urgent healthcare problem - Sepsis Sepsis is the leading cause of death in U.S. hospitals1), killing >500,000 people yearly in the EU and US2) Sepsis is also the #1 hospitalization cost in the US with over $24bn yearly3) Mortality increases 7.6% for every hour of delayed tr
Slide 6: Q-linea provides actionable results in sepsis diagnosis
Q-linea provides actionable results in sepsis diagnosis Identification analysis (ID) – “What bug” ASTar™ § To determine identity of the causative pathogen e.g. E. coli bacteria § And if applicable determine the presence of resistance genes e.g. MecA (expressed by many MRSA bacteria) Antibiotic susce
Slide 7: Health economic benefits of 24h faster AST on septic patients
Health economic benefits of 24h faster AST1) on septic patients Rapid and efficient solution results in significant health economic benefits Lower mortality Less pressure for Decreased length of resistance and stay and reduced superinfections severity Up to 40% lower mortality rates2) Up to 25%3) re
Slide 8: Key events during the full year 2018
Key events during the full year 2018 • Listing on Nasdaq Stockholm in December, shares corresponding to a value of SEK 550 million were subscribed for • Umbrella Science acquired in an asset deal • Participation at ECCMID, ASM and IDWeek x • Signed agreement with all partners for upcoming EU clinica
Slide 9: Income statement fourth quarter
Income statement fourth quarter • Net sales in the fourth quarter amounted to SEK 0.3 million (1.5). • Operating result totalled SEK -39.0 million (-21.8). x • The company reported a loss after tax of SEK -39.4 million (-21.9). • Earnings per share amounted to SEK -2.33 (-1.90). Source: Company info
Slide 10: Balance sheet at year end
Balance sheet at year end • Cash and cash equivalents amounted to SEK 354 million (6.6). • Fixed income fund at SEK 150 million. x • Interest-free short-term loan from Nexttobe AB of SEK 12.8 million repaid in December. Source: Company information. Strictly private and confidential 10 10
Slide 11: Cash flow statement fourth quarter
Cash flow statement fourth quarter • Cash flow from operating activities SEK -37.4 million (-21.1). • Increased cash outflow from operating activities mainly due to a larger operating loss. x • Cash flow from financing activities SEK 492 million (13), (SEK 635 million (63) for full year) Source: Com
Slide 12: Q&A
Q&A Strictly private and confidential 12